Should I Buy LYRA? LYRA 2026 Analysis

Should You Buy Lyra Therapeutics Inc (LYRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

2.040

1 Day change

-0.49%

52 Week Range

37.500

Analysis Updated At

2026/01/30

Not a good buy right now. LYRA is in a bearish technical trend with no proprietary buy signals, no supportive options flow/liquidity, no fresh news catalysts, and weak latest-quarter fundamentals. For an impatient buyer, the current setup does not justify jumping in; I would avoid/exit rather than buy.

Technical Analysis

**Trend/Price Action**: Bearish bias. The moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend. **Momentum**: MACD histogram is negative (-0.00108) and still below zero (bearish), though contracting (selling pressure easing slightly, but not a reversal signal). **RSI**: RSI_6 = 44.19 (neutral-to-bearish), showing no strong oversold bounce signal. **Key Levels**: Pivot 2.07 is overhead (price 2.04 below pivot = weak). Resistance at R1 2.444 then R2 2.676. Support at S1 1.696 then S2 1.464—meaning downside risk to ~1.70 is plausible if weakness persists. **Pattern-based expectation**: Similar-pattern stats suggest a mild negative next day (-1.12%) but potentially positive 1-week (+2.22%) and 1-month (+25.34%)—however, this is counter to the current bearish trend stack and lacks confirmation. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options sentiment is effectively **not readable** because both open interest and volume are reported as 0 (no meaningful positioning/flow). Despite that, reported volatility metrics are extreme (30D IV ~492.67% vs historical vol ~107.18%), which typically implies a highly speculative name and/or unreliable quotes due to illiquidity. IV percentile/rank (~24) suggests IV is not at the top of its own recent range, but with zero activity, this is not a strong sentiment input.

Technical Summary

Sell

Buy

Positive Catalysts

- Next earnings date: 2026-02-11 (after hours). A microcap biotech can move sharply around earnings.
- If price reclaims the pivot (2.07) and holds above it, a short-term squeeze toward 2.44 could become technically feasible (needs confirmation).

Neutral/Negative Catalysts

- Clear bearish trend (SMA_200 > SMA_20 > SMA_5) and price below pivot (2.07).
- No Intellectia buy signals (no AI Stock Picker pre-market buy / no SwingMax entry).
- No news catalysts in the last week; nothing event-driven supporting an immediate upside move.
- Options market shows zero OI/volume, indicating poor liquidity and lack of supportive positioning.
- Microcap profile (market cap shown as ~$3.59M) tends to amplify downside moves when sentiment fades.

Financial Performance

Latest reported quarter: **2025/Q3**. - Revenue: **$25K**, **-87.18% YoY** (sharp contraction). - Net income: **-$5.984M**, **-49.60% YoY** (still deeply loss-making). - EPS: **-3.38**, **-62.73% YoY** (worsening per-share losses). - Gross margin: **100%** (not very informative here given minimal revenue). Overall: fundamentals show severe revenue decline and continued losses—no visible improving growth trend in the latest quarter data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there’s no identifiable recent trend in upgrades/downgrades or target revisions. With the available data (microcap size, weak quarter, bearish trend, no catalysts), the implied Wall Street-style balance of pros/cons skews negative: upside would rely on event-driven biotech outcomes rather than demonstrated operating momentum.

Analyst Rating

Wall Street analysts forecast LYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYRA is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 2.050

Low

Averages

High

Current: 2.050

Low

Averages

High

H.C. Wainwright

Neutral

upgrade

$2 -> $16

AI Analysis

2025-06-10

Reason

H.C. Wainwright

Price Target

$2 -> $16

AI Analysis

2025-06-10

upgrade

Neutral

Reason

H.C. Wainwright raised the firm's price target on Lyra Therapeutics to $16 from $2 and keeps a Neutral rating on the shares following the company's reverse stock split.

HC Wainwright & Co.

Matthew Caufield

Hold

Reiterates

2025-03-14

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

2025-03-14

Reiterates

Hold

Reason

LYRA Should I Buy

LYRA Should I Buy

Should You Buy Lyra Therapeutics Inc (LYRA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch